HCT-116人结直肠腺癌细胞

HCT116/HCT116细胞系/HCT116细胞株/HCT116人结肠癌细胞

Cell line name HCT 116

Synonyms HCT-116; HCT.116; HCT_116; HCT116; HCT116wt; CoCL2

Accession CVCL_0291

Resource Identification Initiative To cite this cell line use: HCT 116 (RRID:CVCL_0291)

Comments Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: ENCODE project common cell types; tier 3.

Part of: FGFR genetic alteration cell panel (ATCC TCP-1034).

Part of: JFCR39 cancer cell line panel.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI RAS program mutant KRAS cell line panel.

Part of: NCI-60 cancer cell line panel.

Population: Caucasian.

Doubling time: 17.1 hours (PubMed=22628656); 22 hours (PubMed=23546019); 25.02 hours (PubMed=25944804); 36 hours (PubMed=25984343); 18.14 +- 0.051 hours (PubMed=32927768); ~25-48 hours (DSMZ=ACC-581); 17.4 hours (NCI-DTP=HCT-116); ~21 hours (PBCF).

Microsatellite instability: Instable (MSI-high) (PubMed=9000147; PubMed=10674020; PubMed=12714694; PubMed=23671654; PubMed=24042735; PubMed=24755471; PubMed=25926053; PubMed=28683746; PubMed=31068700; Sanger).

Omics: Array-based CGH.

Omics: CTCF ChIP-seq epigenome analysis.

Omics: H3K4me3 ChIP-seq epigenome analysis.

Omics: CNV analysis.

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Extracellular vesicles proteome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative phosphoproteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: HLA class I peptidome analysis by proteomics.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: miRNA expression profiling.

Omics: N-glycan profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by massively parallel signature sequencing (MPSS).

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).

Misspelling: HCT-166; Note=In a BTO entry (BTO:0004743) now obsoleted.

Misspelling: HTC 116; Note=Occasionally.

Misspelling: HTC-116; Note=Occasionally.

Misspelling: Htc-116; Note=Occasionally.

Misspelling: HTC116; Note=Occasionally.

Misspelling: HTC1116; Note=Occasionally.

Derived from site: In situ; Colon; UBERON=UBERON_0001155.

PubMed=16418264; DOI=10.1073/pnas.0510146103; PMCID=PMC1327731

Liu Y., Bodmer W.F.

Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines.

Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006)

 

PubMed=16854228; DOI=10.1186/1476-4598-5-29; PMCID=PMC1550420

Bandres Elizalde E.M., Cubedo E., Agirre X., Malumbres R., Zarate R., Ramirez N., Abajo A., Navarro A., Moreno I., Monzo M., Garcia-Foncillas J.

Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.

Mol. Cancer 5:29.1-29.10(2006)

 

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miarker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)

 

PubMed=17178751; DOI=10.1093/nar/gkl1030; PMCID=PMC1807964

Fiegler H., Geigl J.B., Langer S., Rigler D., Porter K., Unger K., Carter N.P., Speicher M.R.

High resolution array-CGH analysis of single cells.

Nucleic Acids Res. 35:e15.1-e15.10(2007)

 

PubMed=17363507; DOI=10.1158/1535-7163.MCT-06-0555

Wang J., Kuropatwinski K.K., Hauser J., Rossi M.R., Zhou Y.-F., Conway A., Kan J.L.C., Gibson N.W., Willson J.K.V., Cowell J.K., Brattain M.G.

Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.

Mol. Cancer Ther. 6:1143-1150(2007)

 

PubMed=18258742; DOI=10.1073/pnas.0712176105; PMCID=PMC2268141

Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.

Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008)

 

PubMed=18340113; DOI=10.4161/cbt.7.6.5838

Gongora C., Candeil L., Vezzio-Vie N., Copois V., Denis V., Bareil C., Molina F., Fraslon C., Conseiller E., Pau B., Martineau P., Del Rio M.

Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.

Cancer Biol. Ther. 7:822-832(2008)

 

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)

 

PubMed=19927377; DOI=10.1002/gcc.20730; PMCID=PMC2818350

Knutsen T., Padilla-Nash H.M., Wangsa D., Barenboim-Stapleton L., Camps J., McNeil N.E., Difilippantonio M.J., Ried T.

Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.

Genes Chromosomes Cancer 49:204-223(2010)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192; PMCID=PMC2943514

Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S., Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M., Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M., Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Cancer Res. 70:5901-5911(2010)